JP2017530372A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530372A5 JP2017530372A5 JP2017533704A JP2017533704A JP2017530372A5 JP 2017530372 A5 JP2017530372 A5 JP 2017530372A5 JP 2017533704 A JP2017533704 A JP 2017533704A JP 2017533704 A JP2017533704 A JP 2017533704A JP 2017530372 A5 JP2017530372 A5 JP 2017530372A5
- Authority
- JP
- Japan
- Prior art keywords
- vegf
- pharmaceutical composition
- patient
- domain
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 17
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 17
- 238000000034 method Methods 0.000 claims 11
- 239000005557 antagonist Substances 0.000 claims 9
- 238000000338 in vitro Methods 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims 7
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 6
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 4
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 4
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- 108010081667 aflibercept Proteins 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 229960002760 ziv-aflibercept Drugs 0.000 claims 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051091P | 2014-09-16 | 2014-09-16 | |
| US62/051,091 | 2014-09-16 | ||
| US201562099630P | 2015-01-05 | 2015-01-05 | |
| US62/099,630 | 2015-01-05 | ||
| PCT/US2015/049279 WO2016044041A1 (en) | 2014-09-16 | 2015-09-10 | Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530372A JP2017530372A (ja) | 2017-10-12 |
| JP2017530372A5 true JP2017530372A5 (enExample) | 2018-10-11 |
| JP6692358B2 JP6692358B2 (ja) | 2020-05-13 |
Family
ID=54207741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533704A Active JP6692358B2 (ja) | 2014-09-16 | 2015-09-10 | 転移性結腸直腸癌の抗血管新生療法に関連する予測的及び予後的バイオマーカー |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10525104B2 (enExample) |
| EP (1) | EP3194974B1 (enExample) |
| JP (1) | JP6692358B2 (enExample) |
| KR (1) | KR102471057B1 (enExample) |
| CN (1) | CN107076749B (enExample) |
| AU (1) | AU2015318207B2 (enExample) |
| CA (1) | CA2960890A1 (enExample) |
| EA (1) | EA036671B1 (enExample) |
| IL (1) | IL250905B (enExample) |
| MX (1) | MX382673B (enExample) |
| WO (1) | WO2016044041A1 (enExample) |
| ZA (1) | ZA201701664B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11699527B2 (en) | 2013-03-14 | 2023-07-11 | Otraces, Inc. | Method for improving disease diagnosis using measured analytes |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| JP6952056B2 (ja) | 2016-01-22 | 2021-10-20 | オートレイシーズ, インク.Otraces, Inc. | 疾患診断を改善するシステム及び方法 |
| CA3058129C (en) * | 2017-03-31 | 2023-04-18 | Hirotsu Bio Science Inc. | Method for predicting therapeutic effect and/or recurrence monitoring in cancer patients |
| US11524053B2 (en) | 2018-01-26 | 2022-12-13 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| WO2020165483A1 (es) * | 2019-02-15 | 2020-08-20 | Universidad de Córdoba | Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos |
| JP2022541689A (ja) * | 2019-07-13 | 2022-09-26 | オートレイシーズ，インク． | 腫瘍微小環境活性蛋白質を用いる種々の疾患の診断の改善 |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021076852A1 (en) * | 2019-10-17 | 2021-04-22 | Board Of Regents, The University Of Texas System | Small extracellular vesicle-associated vegf as a predictor for therapeutic responses |
| IL293131A (en) | 2019-11-25 | 2022-07-01 | Univ California | Long-acting vegf inhibitors for intraocular neovascularization |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| CN101283280A (zh) * | 2005-08-18 | 2008-10-08 | Zadec私人有限公司 | 用于诊断结直肠癌的蛋白质标记和所述标记作为所述癌症类型治疗的药物靶点的用途 |
| IN2012DN02046A (enExample) * | 2009-08-14 | 2015-08-21 | Allergan Inc | |
| CN102711830A (zh) | 2010-01-19 | 2012-10-03 | 霍夫曼-拉罗奇有限公司 | 用于贝伐单抗联合疗法的基于肿瘤组织的生物标志 |
| SG10201505593VA (en) * | 2010-07-19 | 2015-09-29 | Hoffmann La Roche | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
-
2015
- 2015-09-10 CN CN201580049558.1A patent/CN107076749B/zh active Active
- 2015-09-10 US US15/509,461 patent/US10525104B2/en active Active
- 2015-09-10 EA EA201790549A patent/EA036671B1/ru unknown
- 2015-09-10 EP EP15771819.8A patent/EP3194974B1/en active Active
- 2015-09-10 KR KR1020177007326A patent/KR102471057B1/ko active Active
- 2015-09-10 MX MX2017003387A patent/MX382673B/es unknown
- 2015-09-10 CA CA2960890A patent/CA2960890A1/en active Pending
- 2015-09-10 AU AU2015318207A patent/AU2015318207B2/en active Active
- 2015-09-10 JP JP2017533704A patent/JP6692358B2/ja active Active
- 2015-09-10 WO PCT/US2015/049279 patent/WO2016044041A1/en not_active Ceased
-
2017
- 2017-03-02 IL IL250905A patent/IL250905B/en active IP Right Grant
- 2017-03-08 ZA ZA2017/01664A patent/ZA201701664B/en unknown
-
2019
- 2019-11-21 US US16/690,459 patent/US11439683B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530372A5 (enExample) | ||
| Pestana et al. | Histology-agnostic drug development—considering issues beyond the tissue | |
| Barr Kumarakulasinghe et al. | Molecular targeted therapy in the treatment of advanced stage non‐small cell lung cancer (NSCLC) | |
| Lurje et al. | EGFR signaling and drug discovery | |
| Chuma et al. | New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions | |
| Gossage et al. | Targeting multiple kinase pathways: a change in paradigm | |
| JP2016539096A5 (enExample) | ||
| Greenall et al. | EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications | |
| Wu et al. | Pre-and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro-or macro-metastatic disease | |
| RU2016141385A (ru) | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf | |
| Mittal et al. | Recent advances in targeted therapy for glioblastoma | |
| Wang et al. | New strategies in esophageal carcinoma: translational insights from signaling pathways and immune checkpoints | |
| Kordbacheh et al. | Current and emerging molecular therapies for head and neck squamous cell carcinoma | |
| Mazzola et al. | Targeting the VEGF pathway in metastatic bladder cancer | |
| JP2015525230A5 (enExample) | ||
| JP2016527221A5 (enExample) | ||
| JP2015529641A5 (enExample) | ||
| JP2017501137A5 (enExample) | ||
| HRP20191145T1 (hr) | Postupak predviđanja ishoda liječenja s afliberceptom kod pacijenta za kojeg se sumnja da ima rak | |
| JP2017503481A5 (enExample) | ||
| JP2017523776A5 (enExample) | ||
| Yu et al. | Targeted therapy for advanced or metastatic cholangiocarcinoma: focus on the clinical potential of infigratinib | |
| Ward et al. | Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis | |
| Pirker et al. | Alectinib in RET-rearranged non-small cell lung cancer—Another progress in precision medicine? | |
| JP2016514130A5 (enExample) |